165 related articles for article (PubMed ID: 38458809)
21. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
22. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
23. Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres.
Fennell D; Griffiths D; Eminton Z; Morgan-Fox A; Hill K; Ewings S; Stuart C; Johnson L; Mallard K; Nye M; Darlison L; Dulloo S; Cave J; Luo JL; Taylor P; Spicer J; Poile C; Bzura A; Griffiths G
BMJ Open; 2023 Nov; 13(11):e073120. PubMed ID: 37993149
[TBL] [Abstract][Full Text] [Related]
24. LUMOS - Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS at relapse: Protocol for a pilot study.
Kong BY; Sim HW; Nowak AK; Yip S; Barnes EH; Day BW; Buckland ME; Verhaak R; Johns T; Robinson C; Thomas MA; Giardina T; Lwin Z; Scott AM; Parkinson J; Jeffree R; Lourenco RA; Hovey EJ; Cher LM; Kichendasse G; Khasraw M; Hall M; Tu E; Amanuel B; Koh ES; Gan HK
BMJ Open; 2021 Dec; 11(12):e054075. PubMed ID: 37185327
[TBL] [Abstract][Full Text] [Related]
25. [
Koh ES; Gan HK; Senko C; Francis RJ; Ebert M; Lee ST; Lau E; Khasraw M; Nowak AK; Bailey DL; Moffat BA; Fitt G; Hicks RJ; Coffey R; Verhaak R; Walsh KM; Barnes EH; De Abreu Lourenco R; Rosenthal M; Adda L; Foroudi F; Lasocki A; Moore A; Thomas PA; Roach P; Back M; Leonard R; Scott AM
BMJ Open; 2023 Aug; 13(8):e071327. PubMed ID: 37541751
[TBL] [Abstract][Full Text] [Related]
26. A multicenter phase II study of temozolomide plus disulfiram and copper for recurrent temozolomide-resistant glioblastoma.
Huang J; Chaudhary R; Cohen AL; Fink K; Goldlust S; Boockvar J; Chinnaiyan P; Wan L; Marcus S; Campian JL
J Neurooncol; 2019 May; 142(3):537-544. PubMed ID: 30771200
[TBL] [Abstract][Full Text] [Related]
27. Disulfiram repurposing combined with nutritional copper supplement as add-on to chemotherapy in recurrent glioblastoma (DIRECT): Study protocol for a randomized controlled trial.
Jakola AS; Werlenius K; Mudaisi M; Hylin S; Kinhult S; Bartek J; Salvesen Ø; Carlsen SM; Strandéus M; Lindskog M; Löfgren D; Rydenhag B; Carstam L; Gulati S; Solheim O; Bartek J; Solheim T
F1000Res; 2018; 7():1797. PubMed ID: 30647912
[No Abstract] [Full Text] [Related]
28. Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT).
Hanna CR; O'Cathail SM; Graham JS; Saunders M; Samuel L; Harrison M; Devlin L; Edwards J; Gaya DR; Kelly CA; Lewsley LA; Maka N; Morrison P; Dinnett L; Dillon S; Gourlay J; Platt JJ; Thomson F; Adams RA; Roxburgh CSD
Radiat Oncol; 2021 Aug; 16(1):163. PubMed ID: 34446053
[TBL] [Abstract][Full Text] [Related]
29. A phase III randomized trial evaluating chemotherapy followed by pelvic reirradiation versus chemotherapy alone as preoperative treatment for locally recurrent rectal cancer - GRECCAR 15 trial protocol.
Denost Q; Frison E; Salut C; Sitta R; Rullier A; Harji D; Maillou-Martinaud H; Rullier E; Smith D; Vendrely V;
Colorectal Dis; 2021 Jul; 23(7):1909-1918. PubMed ID: 33843133
[TBL] [Abstract][Full Text] [Related]
30. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
[TBL] [Abstract][Full Text] [Related]
31. Multi-Arm GlioblastoMa Australasia (MAGMA): protocol for a multiarm randomised clinical trial for people affected by glioblastoma.
Kong BY; Sim HW; Barnes EH; Nowak AK; Hovey EJ; Jeffree R; Harrup R; Parkinson J; Gan HK; Pinkham MB; Yip S; Hall M; Tu E; Carter C; Koh ES; Lwin Z; Dowling A; Simes JS; Gedye C
BMJ Open; 2022 Sep; 12(9):e058107. PubMed ID: 36104135
[TBL] [Abstract][Full Text] [Related]
32. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
33. Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse.
Brada M; Hoang-Xuan K; Rampling R; Dietrich PY; Dirix LY; Macdonald D; Heimans JJ; Zonnenberg BA; Bravo-Marques JM; Henriksson R; Stupp R; Yue N; Bruner J; Dugan M; Rao S; Zaknoen S
Ann Oncol; 2001 Feb; 12(2):259-66. PubMed ID: 11300335
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial.
Lieverse RIY; Van Limbergen EJ; Oberije CJG; Troost EGC; Hadrup SR; Dingemans AC; Hendriks LEL; Eckert F; Hiley C; Dooms C; Lievens Y; de Jong MC; Bussink J; Geets X; Valentini V; Elia G; Neri D; Billiet C; Abdollahi A; Pasquier D; Boisselier P; Yaromina A; De Ruysscher D; Dubois LJ; Lambin P
BMC Cancer; 2020 Jun; 20(1):557. PubMed ID: 32539805
[TBL] [Abstract][Full Text] [Related]
35. Stereotactic Radiotherapy in Recurrent Glioblastoma: A Valid Salvage Treatment Option.
Yaprak G; Isık N; Gemici C; Pekyurek M; Ceylaner Bıcakcı B; Demircioglu F; Tatarlı N
Stereotact Funct Neurosurg; 2020; 98(3):167-175. PubMed ID: 32248188
[TBL] [Abstract][Full Text] [Related]
36. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.
Conibear J; Chia B; Ngai Y; Bates AT; Counsell N; Patel R; Eaton D; Faivre-Finn C; Fenwick J; Forster M; Hanna GG; Harden S; Mayles P; Moinuddin S; Landau D
BMJ Open; 2018 Apr; 8(4):e020690. PubMed ID: 29666135
[TBL] [Abstract][Full Text] [Related]
37. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial.
Dillon R; Maycock S; Jackson A; Fox S; Freeman S; Craddock C; Thomas C; Homer E; Leahy J; Mamwell A; Potter N; Russell N; Wei A; Ommen HB; Hemmaway C; Knapper S; Billingham L
BMC Cancer; 2022 Nov; 22(1):1174. PubMed ID: 36376888
[TBL] [Abstract][Full Text] [Related]
38. Palliative radiotherapy combined with stent insertion to reduce recurrent dysphagia in oesophageal cancer patients: the ROCS RCT.
Adamson D; Blazeby J; Porter C; Hurt C; Griffiths G; Nelson A; Sewell B; Jones M; Svobodova M; Fitzsimmons D; Nixon L; Fitzgibbon J; Thomas S; Millin A; Crosby T; Staffurth J; Byrne A
Health Technol Assess; 2021 May; 25(31):1-144. PubMed ID: 34042566
[TBL] [Abstract][Full Text] [Related]
39. The value of moderate dose escalation for re-irradiation of recurrent or second primary head-and-neck cancer.
Rühle A; Sprave T; Kalckreuth T; Stoian R; Haehl E; Zamboglou C; Laszig R; Knopf A; Grosu AL; Nicolay NH
Radiat Oncol; 2020 Apr; 15(1):81. PubMed ID: 32299456
[TBL] [Abstract][Full Text] [Related]
40. Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: study protocol for a multicenter open-label randomized phase II trial.
Tomita N; Ishiyama H; Makita C; Ohshima Y; Nagai A; Baba F; Kuno M; Otsuka S; Kondo T; Sugie C; Kawai T; Takaoka T; Okazaki D; Torii A; Niwa M; Kita N; Takano S; Kawakami S; Matsuo M; Kumano T; Ito M; Adachi S; Abe S; Murao T; Hiwatashi A
BMC Cancer; 2022 Dec; 22(1):1259. PubMed ID: 36471274
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
